# US 2017/0224809 A1 · Use of superantigens for improving mucosal allergen specific immunotherapy in non-human mammals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0224809 A1
- Document ID: US20170224809A1
- Status: Published application
- Kind: A1
- Application number: 15/519,493
- Filed: 2015-10-09
- Published: 2017-08-10
- Earliest claimed: 2014-10-14
- Assignees: Premune AB
- Applicants: Premune AB
- Inventors: Sofia Östman; Agnes Wold
- Web page: https://patentgrep.com/patent/US20170224809A1

## CPC

- A61K 39/35: Allergens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 2039/541: {Mucosal route}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Use of a superantigen in mucosal allergen specific immune therapy (ASIT) in a non-human mammal to enhance the effect thereof. In order to enhance the effect of the mucosal ASIT, the superantigen is mucosally administered before, or with, the allergen to the non-human mammal.

## Claims

### Claim 1

A method of enhancing the effect of allergen specific immune therapy (ASIT) in a non-human mammal suffering from hypersensitivity towards an allergen, the method comprising the steps of:
administering the allergen to the non-human mammal; and
administering a superantigen before, or with, the allergen to the non-human mammal in need thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the non-human mammal is a dog, a cat, or a horse.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method according to claim 1, wherein the superantigen and the allergen are co-administered.

### Claim 5 (depends on 1)

The method according to claim 1, wherein at least one of the superantigen and the allergen is orally administered.

### Claim 6 (depends on 5)

The method according to claim 5, wherein at least one of the superantigen and the allergen is sublingually administered.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the superantigen is administered less than 18 hours before the administration of the allergen.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the steps of administering the superantigen and the allergen are repeated, the subsequent administration being performed is at least 4 hours after the preceding administration but less than 2 weeks after the preceding administration.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the allergen is formulated for oral administration.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the non-human mammal is at least 6 months old.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said superantigen is selected from the group consisting of: SEA, SEB, SEC1, SEC2, SEC3, SED, SEE, SEG, SEH, SEI, SEJ, SEK, SEL, SEM, SEN, SEO, SEP, SER, SEQ, SEU, SEV, TSST-1, and a mixture thereof.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said superantigen is selected from the group consisting of: SEK, SEL, SEM, SEN, SEO, SEP, SEQ, SEU, and a mixture thereof.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the allergen specific immune therapy (ASIT) targets allergies selected from the group consisting of canine atopic dermatitis (CAD) and food allergy.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the allergen is selected from the group consisting of environmental allergens and food allergens.

### Claim 15

A composition comprising a superantigen, an allergen and at least one pharmaceutical acceptable carrier or excipient.

### Claim 16 (depends on 15)

The composition according to claim 15, wherein the composition is formulated for oral administration.

### Claim 17 (depends on 15)

The composition according to claim 15, wherein the superantigen is selected from the group consisting of: SEA, SEB, SEC1, SEC2, SEC3, SED, SEE, SEG, SEH, SEI, SEJ, SEK, SEL, SEM, SEN, SEO, SEP, SER, SEQ, SEU, SEV, TSST-1, and a mixture thereof.

### Claim 18 (depends on 17)

The composition according to claim 17, wherein the superantigen is selected from the group consisting of: SEK, SEL, SEM, SEN, SEO, SEP, SEQ, SEU, and a mixture thereof.

### Claim 19 (depends on 15)

The composition according to claim 15, wherein the allergen is selected from the group consisting of environmental allergens and food allergens.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 14)

The method according to claim 14, wherein the allergen is selected from the group consisting of tree-pollen, grass-pollen, wood-pollen, house dust mites, mold spores, fleas, beef protein, chicken protein, pork protein, corn protein, wheat protein, soybean protein, and egg protein.

### Claim 24 (depends on 19)

The method according to claim 19, wherein the allergen is selected from the group consisting of tree-pollen, grass-pollen, wood-pollen, house dust mites, mold spores, fleas, beef protein, chicken protein, pork protein, corn protein, wheat protein, soybean protein, and egg protein.

### Claim 25 (depends on 4)

The method according to claim 4, wherein the superantigen and the allergen are formulated into a single composition with at least one pharmaceutically acceptable carrier or excipient.
